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336Pharmacokinetics and Pharmacodynamic Action of
Budesonide after Buccal Administration in Healthy
Subjects and Patients with Oral Chronic
Graft-versus-Host Disease
Karin Dilger,1 Jo¨rg Halter,2 Hartmut Bertz,3 Luis Lopez-Lazaro,4
Alois Gratwohl,2 Ju¨rgen Finke3Buccal administration of budesonide (mouthwash) may be effective as a topical add-on therapy in patients
with oral chronic graft-versus-host disease (cGVHD). Safety of approved oral budesonide is based on high
intestinal and hepatic extraction by cytochrome P450 3A (CYP3A) enzymes. The purpose of this study
was to evaluate the presystemic extraction and pharmacodynamic action of buccal budesonide. Oral bude-
sonide (3 mg) was taken as reference to which various single and multiple dose regimens of buccal budeso-
nide were compared. Budesonide and the 2 main CYP3A-dependent metabolites (6b-hydroxybudesonide,
16a-hydroxyprednisolone) were analyzed in blood and urine along with the drug’s effect on endogenous cor-
tisol in 12 healthy subjects and 7 patients with oral cGVHD. We assessed CYP3A-dependent metabolites in
both healthy subjects and patients after buccal budesonide. Whereas systemic exposure to budesonide was
markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailabil-
ity 18%–36%), the systemic concentrations thereafter in patients were as high as those after the identical
dose of oral budesonide. Reduced buccal CYP3A activity (lower inactivation of budesonide) in patients con-
tributed to this remarkable difference. Endogenous cortisol was suppressed in some patients during 1 week
of continuous treatment with buccal budesonide (3 3 mg per day). We are the first to report the biotrans-
formation of budesonide via CYP3A enzymes after buccal drug administration. Only 2% of a buccal dose of
budesonide achieves systemic circulation in healthy individuals; that fraction is 10% in patients with oral
cGVHD, probably because of alterations in drug uptake and metabolization.
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Mouth and oral cavityINTRODUCTION
Between 20% and 50% of patients surviving more
than 6 months after allogenic hematopoietic stem cell
transplantation (HSCT) for hematologic malignancies
will develop some degree of chronic graft-versus-host
disease (cGVHD) [1]. GVHD is the result of allogenic
T cells (either transferred with the donor’s stem cell
inoculum or developing from it) reacting with anti-Dr. Falk Pharma GmbH, Freiburg, Germany; 2Hematol-
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6/j.bbmt.2008.12.001genic targets on host cells [2]. Its clinical manifesta-
tions determine whether the clinical syndrome of
GVHD is classified as acute (aGVHD) or cGVHD
[3]. Oral cGVHD resembles an autoimmune disorder
with skin, liver, oral, and ocular lesions being the
predominant manifestations [4]. Systemic prednisone,
together with a calcineurin inhibitor such as cyclo-
sporine (CsA) or tacrolimus, is the standard treatment
of cGVHD at present [5]. However, oral cGVHD is
often refractory to conventional therapy [6]. To date,
there is no specific, undisputed treatment of oral
cGVHD that convinces [7,8].
Budesonide is a relatively new synthetic glucocor-
ticoid demonstrating a high ratio of local to systemic
anti-inflammatory activity [9]. Two recent clinical in-
vestigations reported that the buccal administration of
budesonide may be effective as topical add-on therapy
for oral cGVHD [10,11]. Oral budesonide has been
approved for the treatment of mild to moderate exac-
erbations of Crohn’s disease for many years [12].
Biol Blood Marrow Transplant 15:336-343, 2009 337Buccal Budesonide in Oral Chronic GVHDThe low risk of adverse drug reactions to oral budeso-
nide is attributed to its low absolute bioavailability be-
cause of extensive presystemic biotransformation via
cytochrome P450 3A (CYP3A) enzymes into the 2 ma-
jor and pharmacologically inactive metabolites 6b-
hydroxybudesonide and 16a-hydroxyprednisolone [13].
CYP3A enzymes are the most abundant and predomi-
nant drug-metabolizing enzymes in humans [14].
However, unlike the gut and liver, the oral mucosa
has not been thoroughly characterized in terms of its
CYP3A expression [15,16]. There are no data on buc-
cal expression of CYP3A in patients with oral
cGVHD. Therefore, clinical studies on the disposition
of buccal budesonide in patients with oral cGVHD, in-
cluding characterization of the relevant metabolic
pathways, are necessary. A source of concern regarding
the topical administration of budesonide in oral
cGVHD is that it could lead to significant systemic
levels of the steroid. As systemic exposure to topical
steroids and topical tacrolimus has been reported in
several papers [17-19], it is important to know whether
there is a significant degree of direct buccal absorption
of budesonide.
The aim of our trial was thus to determine the
pharmacokinetic profile and pharmacodynamic action
of buccal budesonide following single-dose and
steady-state dosing. A thorough analysis of metabolite
kinetics (formation of 6b-hydroxybudesonide and
16a-hydroxyprednisolone via CYP3A) is provided.
To determine the safe dosing of buccal budesonide,
we aimed to examine its effects on endogenous cortisol
production.MATERIALS AND METHODS
Subjects
Enrolled in this study were 12 healthy subjects (6
females, 6 males; 43.7 6 7.1 years, 71.5 6 10.3 kg)
and 7 patients (1 female, 6 males; 44.4 6 14.0 years,
66.66 9.1 kg) presenting with at least 1 of 5 diagnostic
clinical signs of oral cGVHD (lichen-type features,
hyperkeratotic plaques, ulcers, pseudomembranes, or
decreased oral range of motion in patients with scle-
rotic skin features of GVHD [3,20]). Oral cGVHD
had to have occured beyond 100 days after HSCT
Only patients who presented a lack of complete re-
sponse following conventional first-line treatment
(systemic glucocorticoids and/or calcineurin inhibi-
tors), that is, they still showed signs and symptoms of
oral GVHD, were included. One main exclusion crite-
rion was oral mucositis resulting from chemotherapy
or radiotherapy. Any change in the dosage regimen
of concomitant glucocorticoids or calcineurin inhibi-
tors was not allowed within 3 weeks before and during
the trial; repeated use of CYP3A inducers or inhibitors
was not allowed; an exception was made regarding astable regimen of azole antifungals [21]. Healthy sub-
jects were excluded if they had taken any medications
within 2 weeks before or during the study. Grapefruit
consumption in the week prior to the first study day or
during the trial precluded participation in all subjects.Study Design
First, healthy subjects received aqueous solutions
of budesonide tablets (1 effervescent buccal tablet
containing 3 mg budesonide) in a fixed treatment or-
der comprising 6 different treatments: (1) as a refer-
ence to calculate relative bioavailability of the oral
intake (immediate swallowing) of 10 mL aqueous so-
lution containing 3 mg budesonide [R]; thereafter (2)
a single dose of 10 mL aqueous solution containing
3 mg budesonide as a 10-minute mouthwash [SD1];
(3) a single dose of 10 mL aqueous solution contain-
ing 3 mg budesonide as a 5-minute mouthwash
[SD2]; (4) a single dose of 10 mL aqueous solution
containing 6 mg budesonide as a 10-minute mouth-
wash [SD3]; (5) a single dose of 10 mL aqueous so-
lution containing 9 mg budesonide as a 10-minute
mouthwash [SD4]; and finally, (6) multiple doses of
10 mL aqueous solution containing 3 mg budeso-
nide for 7 days (3 times per day, making a total daily
dose of 9 mg) as a 10-minute mouthwash, with the
last mouthwash on the morning of day 7 [MD1].
Second, patients with oral cGVHD received aqueous
solutions of budesonide via only 3 of the above
treatments: (1) for reference purposes, the oral in-
take of 10 mL aqueous solution containing 3 mg bu-
desonide [R]; thereafter (2) a single dose of 10 mL
aqueous solution containing 3 mg budesonide as
a 10-minute mouthwash [SD1]; and finally, (3) mul-
tiple doses of 10ml aqueous solution containing 3
mg budesonide for 7 days (3 times per day, making
a total daily dose of 9 mg) as a 10-minute mouth-
wash with the final mouthwash on the morning of
day 7 [MD1]. Correct oral intake and correct buccal
drug administration (eg, keeping the solution in the
mouth for 10 minutes before expectorating) was su-
pervised by an investigator. Single-dose administra-
tions were separated by a washout of at least 3
days, the multiple-dose period followed the last sin-
gle-dose administration without a washout. All drug
administrations for pharmacokinetic and dynamic
profiling were performed after an overnight fast,
and subjects continued to fast for another 2 hours;
fluid was not allowed during the first hour after
the mouthwash.
Complete organ staging of cGVHD was carried
out in the patients within 2 weeks prior to the first
study day; skin, mouth, eyes, gastrointestinal tract,
liver, lungs, joints, and fascia and genital tract were
rated separately with each score ranging from 0 to 3
[3]. Systematic clinical assessment of the oral mucosa
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areas examined for the Oral Mucosa Rating Scale
(OMRS) were: upper and lower lips, upper and lower
labial mucosa, right and left buccal mucosa, dorsal
and lateroventral tongue, soft palate. Erythema,
lichenoid hyperkeratosis, and pseudomembranes/ul-
ceration were assigned scores ranging from 0 to 3 re-
sulting in a maximum total score of 81. To identify
any oral mucoceles, we examined the soft palate, lower
labial, and buccal mucosa in a standardized procedure.
Single-dose and steady-state (last day of treatment
MD1) pharmacokinetic and dynamic profiling was
done by measuring budesonide, CYP3A-dependent
metabolites (6b-hydroxybudesonide, 16a-hydroxy-
prednisolone) in plasma and urine, and cortisol in
serum and urine over a period of 12 hours after drug ad-
ministration. To be precise, blood samples for budeso-
nide and metabolites were taken just before and 10, 20,
30, 40, 60, 80, and 100 minutes, as well as 2, 3, 4, 5, 6, 8,
and 12 hours after drug administration; blood samples
for cortisol were taken just before and 2, 4, 6, 8, and 12
hours after drug administration. Urine was collected at
1 interval (0-12 hours). Plasma, serum, and urine were
stored at 220C (\3 months) until analysis.
Analytical Methods
Concentrations of budesonide, 6b-hydroxybude-
sonide, and 16a-hydroxyprednisolone in plasma were
determined by validated liquid chromatography tan-
dem mass spectrometry as described previously [23].
The lower limits of quantification in plasma (urine)
were 0.1 ng/mL (0.5 ng/mL) for budesonide and
6b-hydroxybudesonide, and 0.5 ng/mL (2 ng/mL) for
16a-hydroxyprednisolone. Between-day and within-
day coefficients of variation of quality controls were un-
der 15%. Cortisol in serum and urine was determined
using a solid-phase, competitive chemiluminescent
enzyme immunoassay (IMMULITE 2000, Diagnostic
Products, Los Angeles, CA). Analytical sensitivity of
the test was 0.2 mg/dL.
Pharmacokinetic and Pharmacodynamic
Analyses
Peak plasma concentration (Cmax), and time of
Cmax (tmax) were obtained directly from the plasma
concentration-time curves. The area under the plasma
concentration-time curve (AUC) represents the extent
of systemic drug exposure. AUC and terminal elimina-
tion half-life (t1/2 5 ln[2]/l) were calculated using
standard noncompartmental analysis (WinNonlin v.
4.1, Pharsight Corporation, Mountain View, CA).
The elimination-rate constant (l) was determined by
linear regression analysis of the terminal log-linear
phase of the plasma concentration-time curve. Relative
bioavailability (Frel) of budesonide after buccal admin-
istration as compared to oral intake was calculated by(AUC0-tlast,buccal * oral dose)/(AUC0-tlast,oral * buccal
dose). Rate of accumulation during steady-state dosing
was obtained by the following ratio [24]: Rac 5
AUCss,0-8h/AUC0-8h,SD1. A linearity factor of pharma-
cokinetics after repeated drug administration was
calculated as the ratio of AUCss,0-8h to AUC0-N,SD1.
Molar ratios of metabolite formation (AUCMet/
AUCBudesonide, where Met is the metabolite), such as
AUC0-tlast of 6b-hydroxybudesonide to AUC0-tlast of
budesonide, were used as indices of CYP3A metabolic
activity. Urinary recoveries of the analytes were based
on the cumulative amount of the analyte excreted dur-
ing the 12-hour collection period (Ae0-12h), and ex-
pressed as a percentage of the budesonide dose
administered after correction for molecular weight.
Effects of budesonide on endogenous cortisol produc-
tion were evaluated in each individual by (1) measuring
morning cortisol serum levels (8 A.M.), by (2) calculat-
ing AUC of cortisol in plasma over 12 hours, and by (3)
measuring the cumulative amount of cortisol excreted
into urine over 12 hours.
Statistical Analysis
The number of subjects was chosen in accordance
with accepted guidelines for investigating bioavailabil-
ity [25]. All parameters are given as mean6 SD or me-
dian with range in parentheses. Repeated-measures
ANOVA was performed to assess differences between
the treatments in each group of subjects. Differences in
pharmacokinetic parameters between healthy subjects
and patients with oral cGVHD were tested for signif-
icance using the Mann-Whitney test. P \ .05 was
regarded as statistically significant. Statistical compar-
ison was carried out using GraphPad Instat software
(GraphPad Software, Inc., San Diego, CA).
Ethical Considerations
The study protocol was approved by the institu-
tional ethics committees of the participating centers.
The trial was conducted from February 2006 until
October 2007 in accordance with the ethical guidelines
of the Declaration of Helsinki, and International Con-
ference on Harmonization guidelines for Good Clinical
Practice. All participants gave written informed consent.
Budesonide was designated as an orphan medicinal
product in the European Union intended for the treat-
ment of resistant oral cGVHD (EU/3/06/413).RESULTS
All participants completed the study according to
the protocol with excellent compliance. New onset
of oral candidiasis was reported in 2 patients. There
were no significant changes in how the oral mucosa
was rated during the trial (17.4 6 4.2 versus 15.4 6
10.0, OMRS).
Table 1. Absorption of Budesonide in 12 Healthy Subjects following Five Different Single Dose Administrations
Cmax (ng/mL) tmax (hours) AUC0-tlast (h*ng/mL) Frel (%)
R, oral intake (3 mg) 1.23 ± 0.52*** 1.2 (0.3-1.7)* 2.67 ± 1.09###,## (comparator)
SD1, buccal (3 mg, 10-minute mouthwash) 0.18 ± 0.10 1.7 (1.3-4.0) 0.35 ± 0.35 18 ± 22
SD2, buccal (3 mg, 5-minute mouthwash) 0.27 ± 0.12 1.7 (0.7-2.0) 0.71 ± 0.57 36 ± 32#
SD3, buccal (6 mg, 10-minute mouthwash) 0.41 ± 0.22 1.7 (1.0-2.0) 1.30 ± 0.83$$ 33 ± 30
SD4, buccal (9 mg, 10-minute mouthwash) 0.66 ± 0.36**,* 1.7 (1.0-2.0) 2.06 ± 1.20$$$,$$ 32 ± 24
Cmax indicates maximum plasma concentration; tmax, time to maximum plasma concentration; AUC0-tlast, area under the plasma concentration-time
curve until last observed concentration; Frel, relative bioavailability comparing buccal with oral drug administration.
***P < .001 versus SD1-4; **P < .01 versus SD1; *P < .05 versus SD2; #P < .05 versus SD1; ##P < .01 versus SD3; ###P < .001 versus SD1-2; $$P < .01
versus SD2; $$$P < .001 versus SD1; repeated-measures ANOVA.
Mean 6 SD or median with range in parentheses.
Figure 1. Plasma budesonide concentration-time curves in 12 healthy
subjects following 5 different treatments with single doses of budeso-
nide: R (oral intake); SD1, SD2, SD3, SD4 (mouthwash, for details see
study design). Data are presented as mean.
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Healthy subjects
Pharmacokinetic parameters of budesonide
following the 5 different single dose administrations
are given in Table 1. Corresponding plasma concen-
tration-time curves are shown in Figure 1. Systemic
exposure to budesonide was markedly lower after buc-
cal drug administration than after oral dosing (see
mean Frel of budesonide, 18%-36%). Comparison of
peak plasma concentrations (Cmax) and AUC, which
are the major parameters characterizing drug absorp-
tion, revealed higher systemic drug exposure following
the administration of higher doses of buccal budeso-
nide. Formation of CYP3A-dependent metabolites,
in particular that of 6b-hydroxybudesonide, was
higher after the oral intake of budesonide (4.7 6 1.7,
AUC6b-hydroxybudesonide/AUCBudesonide) than after buc-
cal drug administration (P\0.001 versus each mouth-
wash), with no significant differences among the 4
buccal administrations (1.0 6 1.0, SD1; 0.9 6 0.4,
SD2; 1.76 0.7, SD3, 1.96 0.7, SD4). Repeated doses
of buccal budesonide (3  3 mg per day) over 1 week
resulted in minor systemic drug accumulation (1.6 6
0.6, budesonide; 1.8 6 0.6, 6b-hydroxybudesonide;
1.4 6 0.6, 16a-hydroxyprednisolone; Rac).
Patients with Oral cGVHD
The patients’ demographic and clinical features
are listed in Table 2. The comparison of oral and buc-
cal drug disposition in healthy subjects and patients is
illustrated in Figure 2. Pharmacokinetic parameters
following the first mouthwash are listed in Table 3
(comparing healthy and ill states). Statistical analysis
revealed significant differences in Cmax and AUC of
budesonide between healthy subjects and patients.
Surprisingly, the patients’ systemic exposure to bude-
sonide after buccal administration resembled that after
oral dosing (Table 3, mean Frel of budesonide mouth-
wash 100%); this was not the case in healthy subjects.
Formation of CYP3A-dependent metabolites of bude-
sonide was observed in healthy subjects and patients.
Ratios of metabolite formation reflecting CYP3A
activity are presented in Figure 3. Formation of16a-hydroxyprednisolone (but not that of 6b-hydrox-
ybudesonide) was significantly impaired after buccal
drug administration in patients with oral cGVHD in
comparison to healthy subjects. As had been the case
in healthy subjects, steady-state dosing resulted in mi-
nor systemic drug accumulation in patients (Rac: 1.86
0.9, budesonide; 2.66 2.1, 6b-hydroxybudesonide; 2.3
6 2.0, 16a-hydroxyprednisolone). The linearity factor
based on AUC of budesonide was 1.36 0.6 in both pa-
tients and healthy subjects.
Pharmacodynamic Action
Predose morning serum cortisol (normal 5-25 mg/
dL) on the first study day was lower in patients (range:
4.95-8.08 mg/dL) than in healthy subjects (range:
10.92-14.01 mg/dL). This finding may result from co-
medications; 6 of 7 patients were on a stable dose of
oral prednisone (see Table 2). Most relevant for evalu-
ating the pharmacodynamics of buccal budesonide is
the comparison of morning serum cortisol at baseline
(R) with that after 1 week of continuous treatment
(MD1). The patients’ values were 7.18 6 6.16 mg/dL
for R and 4.95 6 5.84 mg/dL for MD1, and 11.73 6
4.06 mg/dL for R, and 14.01 6 4.34 mg/dL for MD1
in healthy subjects, respectively (no significant
changes). After 1 week of budesonide-rinsing (MD1)
we observed suppressed cortisol profiles (AUC) in 4
Table 2. Demographic and Clinical Features of the Patient Population at Baseline
Patient
Age
(Years)
Sex
(m/f)
Height
(cm)
Weight
(kg)
Organ Scoring of
cGVHD (0-3)* [3] OMRS (0-81) [22] Oral Mucoceles
Concomitant
Prednisone (Oral Dose
per Day, Duration)
1 53 M 181 64 mouth 2, eyes 2, GI
tract 1, lungs 2
13 +++ 4.5 mg, 121 days
2 48 F 156 64 skin 2, mouth 2, eyes 1,
lungs 1
12 — —
3 59 M 183 71 mouth 2, eyes 2, GI
tract 2
24 — 12.5 mg, 35 days
4 32 M 175 50 skin 2, mouth 2, eyes 2,
GI tract 1, joints and
fascia 1
18 — 15 mg, 81 days
5 60 M 182 80 skin 1, mouth 1, eyes 3,
liver 2, joints and
fascia 1, genital tract
2
19 + 5 mg, 54 days
6 34 M 172 67 mouth 2, eyes 1 , 16 — 10 mg,† 106 days
7 25 M 192 70 skin 1, mouth 2, GI tract
1, liver 1
20 + 20 mg, 74 days
Mean 44.4 177.3 66.6 17.4 9.6 mg, 79 days
SD 14.0 11.3 9.1 4.2 6.9 mg, 32 days
GVHD indicates graft-versus-host-disease; OMRS, oral mucosa rating scale; GI, gastrointestinal.
*Organ with score 0 (no symptoms/normal) not given.
†Fifteen milligrams during the initial 35 of 106 days.
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significantly correlate to dose or duration of concom-
itant oral prednisone (Spearman rank correlation).
Likewise, urinary cortisol excretion was lower in pa-
tients with oral cGVHD than in healthy subjects.
We observed a dose-response relationship with uri-
nary amounts of cortisol decreasing with higher daily
doses of buccal budesonide in healthy subjects. The
effect of budesonide on endogenous cortisol in healthy
subjects and patients is summarized in Table 4.Figure 2. Plasma budesonide concentration-time curves in 12 healthy
subjects (square) and 7 patients with oral cGVHD (circle) following a sin-
gle dose of 3 mg budesonide taken orally (open) or administered buc-
cally (closed). Data are presented as mean 6 SD.DISCUSSION
This is the first report on the systemic bioavailabil-
ity of budesonide after buccal administration. Our
study provides comprehensive data on the pharmaco-
kinetics and pharmacodynamic action of buccal bude-
sonide in healthy subjects and patients with oral
cGVHD. Oral intake of budesonide was chosen as
the reference standard to which we compared the buc-
cal administrations of budesonide. Budesonide is
regarded as a sensitive substrate of CYP3A enzymes
[26]. Because budesonide is eliminated via degradation
into inactive phase-I metabolites, its elimination clear-
ance largely depends on the activity of these drug-
metabolizing enzymes. In humans, approximately
60% of the total hepatic CYPs belong to the CYP3A
subfamily [27]. CYP3A is the main CYP found in the
small intestinal epithelia and livers of adult humans
[28,29].
Physiologically speaking, the blood supply from
the gastrointestinal tract passes through the gut and
liver on its way to the heart and lungs. The entire
dose of oral budesonide is thus subject to extensivepresystemic extraction. According to the literature,
oral budesonide has a very low absolute bioavailability
(Fabs) of only 10% because of a high first-pass effect
[30]. It is important to emphasize the distinction
between absolute and relative bioavalability [31].
Absolute bioavailability of oral budesonide is the mea-
sure of systemic exposure of orally dosed budesonide
relative to intravenously given budesonide. The rela-
tive bioavailability (Frel) of buccal budesonide calcu-
lated in our trial describes the systemic exposure
after budesonide mouthwash compared to an accepted
standard (oral budesonide). It follows that only a very
small fraction of buccally applied budesonide reaches
systemic circulation in healthy subjects (about 2% of
the active substance, calculated from 18% [Frel] of
10% [Fabs]). Surprisingly, the buccal-dose fraction
that reaches the systemic circulation is higher in
Table 3. Pharmacokinetic Parameters of Budesonide and 2
CYP3A-DependentMetabolites in 12Healthy Subjects and in 7
Patients with Oral cGVHD following Buccal Drug Adminis-
tration (SD1)
Healthy Subjects Patients
Mann-Whitney
Test
Budesonide
Cmax (ng/mL) 0.18 ± 0.10 0.77 ± 0.23 P < .0001
tmax (h) 1.7 (1.3-4.0) 2.0 (1.0-3.0) n.s.
AUC0-N (h*ng/mL) 1.14 ± 0.39 4.37 ± 1.30 P < .01
t1/2 (h) 2.8 (1.9-5.0) 3.0 (2.5-6.3) n.s.
Frel (%) 18 ± 22 100 ± 98 P < .01
Ae0-12h (% of dose) 0 (0) 0 (0-0.03) n.s.
6b-Hydroxybudesonide
Cmax (ng/mL) 0.15 ± 0.12 0.52 ± 0.28 P < .01
tmax (h) 1.7 (0.7-3.0) 1.8 (1.0-6.0) n.s.
AUC0-N (h*ng/mL) 2.00 ± 1.05 4.41 ± 1.95 P < .01
Ae0-12h (% of dose) 0.16 (0-0.56) 0.24 (0.12-0.53) n.s.
16a-Hydroxyprednisolone
Cmax (ng/mL) 2.39 ± 1.27 5.11 ± 4.91 n.s.
tmax (h) 1.7 (1.0-2.0) 1.8 (1.0-6.0) n.s.
AUC0-N (h*ng/mL) 8.38 ± 3.96 22.32 ± 11.33 P < .01
Ae0-12h (% of dose) 1.21 (0-5.25) 1.21 (1.02-4.52) n.s.
Cmax indicates maximum plasma concentration; tmax, time to maximum
plasma concentration; AUC0-N, area under the plasma concentration-
time curve extrapolated to infinity; t1/2, terminal elimination half-life;
Ae0-12h, amount excreted into urine over 12 hours; n.s., not significant.
Mean 6 SD or median with range in parentheses.
Figure 3. Ratios of CYP3A-dependent metabolite formation following
a single oral dose of 3 mg budesonide by different routes of drug admin-
istration in 12 healthy subjects (white) and 7 patients with oral cGVHD
(black). Data are presented for 6b-hydroxybudesonide (A) and 16a-hy-
droxyprednisolone (B) as mean and SD. P\.001 versus healthy subjects,
Mann-Whitney test. ***P\0.001.
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it does not exceed the fraction of the oral dose reaching
systemic circulation. The blood supply from the oral
cavity passes the oral mucosa as the barrier to drug ab-
sorption on its way to the heart and lungs; it does not
pass through the gut and liver.
CYP3A enzymes were recently detected in the oral
mucosa. Semiquantitative comparison of the DNA
bands revealed that CYP3A5 expression is similar in
human liver and oral buccal-tissue samples [15]. An
RT-PCR analysis by other investigators revealed that
the more common subtype CYP3A4 is also expressed
together with CYP3A5 in human buccal tissue [16].
CYP3A enzymes have not yet been specifically local-
ized in the buccal mucosa. Our clinical results concur
with these preliminary in vitro findings. The parent
compound and both CYP3A-dependent metabolites
were detected in each subject in venous blood samples
after the buccal administration of budesonide. As
shown in our analysis of metabolite kinetics, oral
cGVHD affects buccal CYP3A enzyme activity.
An additional reason behind the obvious difference
in the disposition of budesonide between healthy sub-
jects and patients with oral cGVHD could be altered
drug uptake in the oral mucosa. In contrast to the gas-
trointestinal tract, much less is known about the type
and capacity of drug-transport processes in buccal-
epithelial cells [32]. Budesonide has been identified
as a substrate of the drug-efflux pump P-glycoprotein
that shares considerable substrate-specificity with
CYP3A4 [33]. P-glycoprotein is located in the apical
(luminal) membrane of enterocytes between the duo-
denum and colon [34]. P-glycoprotein limits drugabsorption by pumping its substrates back into the
gut lumen [35]. There are no data on the expression
of P-gp in the oral cavity other than 2 pilot reports
on the expression of P-gp in human gingiva and buccal
epithelium [36,37]. We assume that alterations in drug
transport in the oral cavity of patients with oral
cGVHD result in increased absorption of buccal bude-
sonide. Increased uptake of budesonide via impaired
mucosa (as an underlying reason for higher plasma
levels) is supported by the fact that the elimination
half-life of buccal budesonide was not longer in
patients than in healthy subjects. Further investiga-
tions addressing the role of drug-transporting proteins
and the interplay with drug-metabolizing enzymes in
the human oral cavity (including the analysis of oral
tissue samples) are now warranted from the clinical-
pharmacological perspective.
We cannot definitely exclude minor hepatic
extraction of budesonide because of ‘‘second pass.’’
This may account for some of the reported findings.
The particular role of the hepatic manifestation of
cGVHD for biotransformation of buccal budesonide
could not be determined in this study because of the
low number of patients (2 of 7 patients had liver man-
ifestation). However, this particular aspect is a chal-
lenge for future investigations.
In our trial, pharmacodynamics focused on serum
cortisol concentrations. This method is used to detect
Table 4. Effect of Budesonide on Endogenous Cortisol in 12
Healthy Subjects and 7 Patients withOral c GVHDComparing
Oral Intake (R), Single-Dose Buccal Drug Administration
(SD1), and Buccal Drug Administration after Thrice-Daily
Dosing during 1 Week (MD1)
Evaluation of cortisol R SD1 MD1
C0h (mg/dL)
healthy subjects 11.73 ± 4.06 10.92 ± 3.39 14.01 ± 4.34*
patients 7.18 ± 6.16 8.08 ± 6.65 4.95 ± 5.84##
C12h (mg/dL)
healthy subjects 7.81 ± 8.50 4.92 ± 3.37 3.93 ± 1.84
patients 1.58 ± 1.33### 3.47 ± 2.47 2.20 ± 1.66
AUC0-12h (h*mg/dL)
healthy subjects 73 ± 22 79 ± 27 80 ± 23
patients 34 ± 23## 45 ± 23# 35 ± 25##
Ae0-12h (mg)
healthy subjects 95 ± 64 74 ± 58 44 ± 33*,***
patients 30 ± 33## 22 ± 31## 25 ± 37
C0h indicates predose cortisol plasma concentration (8 A.M.); C12h,
cortisol plasma concentration at 12 hours (8 P.M.); AUC0-12h, area under
the cortisol plasma concentration-time curve during 12 hours;
Ae0-12h, amount of cortisol excreted into urine over 12 hours.
*P < .05 versus SD1, ***P < .001 versus R; repeated-measures ANOVA.
#P < .05 versus healthy subjects, ##P < .01 versus healthy subjects ###P <
.001 versus healthy subjects; Mann-Whitney test.
Data are given as mean 6 SD.
342 Biol Blood Marrow Transplant 15:336-343, 2009K. Dilger et al.adrenal suppression before the appearance of clinical
symptoms. We observed signs of a possible effect on
endogenous cortisol secretion during the brief add-
on use of budesonide mouthwash in patients with
oral cGVHD. This should be examined in more detail
in a subsequent long-term study.
In conclusion, we are the first to report the metab-
olization of buccal budesonide via CYP3A enzymes in
healthy subjects and patients with oral cGVHD. The
remarkable difference in systemic exposure to buccal
budesonide between healthy subjects and patients
seems to be because of the increased drug transport
and impaired CYP3A activity in the oral mucosa of pa-
tients with oral cGVHD. We noted no new signs of
risk associated with the buccal administration of bude-
sonide when considering the known safety profile of
oral budesonide.
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